C
Chengdu Taihe Weiye Biotechnology
Specialized in protecting amino acid and peptide drug intermediates
About Chengdu Taihe Weiye Biotechnology
Chengdu Taihe Weiye Biotechnology, commercially known as Tachem, operates as a specialized manufacturer of protected amino acids, non-natural amino acids, and peptide intermediates. The company was established in 2013 and is headquartered in Chengdu Tianfu International Biological City, China. Its legal representative and major shareholder is Qi Wei.
The firm's business model is centered on the research and development, production, and sale of high-purity chemical raw materials for the global pharmaceutical industry. Revenue is generated through the direct sale of its extensive product catalog, which includes over 1,000 types of protected and non-natural amino acids, as well as custom synthesis services for various impurities and product batches. Tachem serves a client base of large domestic and international pharmaceutical companies, having passed audits from over 40 such entities.
A significant milestone in the company's history was the establishment of a wholly-owned subsidiary, Gansu Tachem Co. Ltd., in 2020. This subsidiary houses the main production base in Lanzhou New Area, featuring standardized factories with an annual output capacity exceeding 200 tons. In 2022, the company further expanded its R&D capabilities by opening a new 3,000-square-meter experimental building in Chengdu, staffed by a research team of over 50 personnel. The company has secured significant funding, including an A+ round of nearly 300 million RMB in late 2023, attracting notable investors like CITIC Securities, Moutai Jinshi Fund, Qiming Venture Partners, and Hillhouse Capital.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 20.3/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotechnology, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Nov 2023 | $41M | $165M | Qiming Venture Partners · GF Xinde Investment · GL Ventures · Jiayuan Venture Capital | ↗ |
| SERIES AOther financing | Aug 2023 | $28M | $110M | CICC · Sunmed Capital · Jiaxing Yuekai Jiahe Venture Capital · Hillhouse Capital | ↗ |
Growth signals
Latest recorded traffic for Chengdu Taihe Weiye Biotechnology is 1K monthly website visits, up 56.3% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Chengdu Taihe Weiye Biotechnology in its local ecosystem
The Chengdu Taihe Weiye Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A12 investors entered at this stage
CICC
Sunmed Capital- JCJiaxing Yuekai Jiahe Venture Capital
Hillhouse Capital- MFMoutai Jinshi Fund
CITIC Securities
Qiming Venture Partners- GIGF Xinde Investment
GL Ventures- JCJiayuan Venture Capital
- HFHonghui Fund
- CQCICC Qichen
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Chengdu Taihe Weiye Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Chengdu Taihe Weiye Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








